Biosceptre’s broad exploitation of its nf-P2X7 technology provides many partnering opportunities.

Within the therapeutics programme there are three products in development: BIL-010t – a topical treatment for skin cancers; BIL-221s – a systemic treatment for various solid tumours and blood cancers; and BIL-200v – a vaccine with potential in a variety of cancer types. The Company is open to discussions on product development and marketing agreements.

To discuss products of interest to your business please contact: